MannKind (MNKD) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
285.5M
Gross Profit
208.9M
73.17%
Operating Income
68.7M
24.06%
Net Income
27.6M
9.66%
EPS (Diluted)
$0.10
Balance Sheet Metrics
Total Assets
393.8M
Total Liabilities
472.7M
Shareholders Equity
-78.8M
Cash Flow Metrics
Operating Cash Flow
34.4M
Free Cash Flow
32.8M
Revenue & Profitability Trend
MannKind Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 285.5M | 199.0M | 99.8M | 75.4M | 65.1M |
| Cost of Goods Sold | 76.6M | 62.8M | 57.5M | 38.9M | 24.6M |
| Gross Profit | 208.9M | 136.2M | 42.3M | 36.6M | 40.5M |
| Operating Expenses | 140.2M | 125.6M | 111.2M | 90.1M | 65.3M |
| Operating Income | 68.7M | 10.6M | -68.9M | -53.5M | -24.8M |
| Pre-tax Income | 30.5M | -10.4M | -87.4M | -80.9M | -57.5M |
| Income Tax | 2.9M | 1.6M | 0 | 0 | -218.0K |
| Net Income | 27.6M | -11.9M | -87.4M | -80.9M | -57.2M |
| EPS (Diluted) | $0.10 | -$0.04 | -$0.34 | -$0.32 | -$0.26 |
Income Statement Trend
MannKind Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 268.3M | 373.4M | 234.9M | 219.5M | 79.5M |
| Non-Current Assets | 125.5M | 101.8M | 60.4M | 101.7M | 29.1M |
| Total Assets | 393.8M | 475.2M | 295.3M | 321.2M | 108.6M |
| Liabilities | |||||
| Current Liabilities | 81.8M | 104.1M | 67.3M | 48.3M | 73.7M |
| Non-Current Liabilities | 390.8M | 617.2M | 478.5M | 482.2M | 215.3M |
| Total Liabilities | 472.7M | 721.4M | 545.8M | 530.5M | 289.0M |
| Equity | |||||
| Total Shareholders Equity | -78.8M | -246.2M | -250.5M | -209.3M | -180.4M |
Balance Sheet Composition
MannKind Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 27.6M | -11.9M | -87.4M | -80.9M | -57.2M |
| Operating Cash Flow | 34.4M | 31.2M | -63.4M | -78.4M | -42.0M |
| Investing Activities | |||||
| Capital Expenditures | -9.7M | -42.4M | -7.6M | -11.5M | -801.0K |
| Investing Cash Flow | -96.6M | -2.0M | 4.9M | -151.5M | 19.2M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | -140.4M | 134.8M | 18.6M | 259.2M | 38.3M |
| Free Cash Flow | 32.8M | -8.3M | -88.3M | -73.2M | -32.9M |
Cash Flow Trend
MannKind Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
37.95
Forward P/E
22.32
Price to Book
-20.66
Price to Sales
3.88
PEG Ratio
22.32
Profitability Ratios
Profit Margin
10.12%
Operating Margin
31.65%
Return on Equity
-35.00%
Return on Assets
10.97%
Financial Health
Current Ratio
2.36
Debt to Equity
-2.62
Beta
1.01
Per Share Data
EPS (TTM)
$0.10
Book Value per Share
-$0.19
Revenue per Share
$1.05
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| mnkd | 1.2B | 37.95 | -20.66 | -35.00% | 10.12% | -2.62 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Vera Therapeutics | 1.4B | -8.41 | 2.58 | -39.49% | 0.00% | 10.18 |
| Immunocore Holdings | 1.6B | -31.41 | 4.13 | -5.86% | -6.48% | 114.67 |
| Agios | 2.1B | 3.17 | 1.44 | 60.26% | 1,798.26% | 3.61 |
Financial data is updated regularly. All figures are in the company's reporting currency.